hs-TnT | n | hs-TnT | n | hs-TnT | n | hs-TnT | n | hs-TnT | n | P values | |
Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | |||||||
(1–5 ng/L) | (6–8 ng/L) | (9–15 ng/L) | (16–28 ng/L) | (>28 ng/L) | |||||||
Clinical characteristics | |||||||||||
Age, years (IQR) | 58 (48–67) | 210 | 62 (55–68) | 284 | 69 (59–74) | 456 | 72 (65–78) | 405 | 73 (65–81) | 424 | <0.001 |
Female gender, n (%) | 80 (38) | 210 | 123 (43) | 284 | 212 (46) | 457 | 165 (41) | 405 | 148 (35) | 424 | 0.01 |
CHA2DS2-VASc (IQR) | 2 (1–3) | 185 | 2 (1–3) | 260 | 3 (2–4) | 434 | 3 (2–4) | 389 | 3 (2–4) | 400 | <0.001 |
Laboratory | |||||||||||
hs-TnT, ng/L (IQR) | 322 (112–720) | 210 | 508 (182–1135) | 284 | 789 (296–2044) | 457 | 1441 (568–3249) | 405 | 2946 (1195–6899) | 424 | <0.001 |
Creatinine, mg/dL (IQR) | 0.9 (0.8–1.0) | 208 | 0.9 (0.8–1.1) | 283 | 1.0 (0.8–1.1) | 453 | 1.1 (0.9–1.3) | 404 | 1.2 (1.0–1.6) | 424 | <0.001 |
Comorbidities | |||||||||||
Heart failure, n (%) | 36 (17.1) | 210 | 55 (19.4) | 284 | 90 (19.7) | 457 | 90 (22.2) | 405 | 129 (30.4) | 424 | <0.001 |
Hypertension, n (%) | 105 (50.0) | 210 | 180 (63.4) | 284 | 309 (67.6) | 457 | 281 (69.4) | 405 | 276 (65.1) | 424 | <0.001 |
DM, n (%) | 13 (6.2) | 210 | 34 (12.0) | 284 | 71 (15.5) | 457 | 69 (17.0) | 405 | 95 (22.4) | 424 | <0.001 |
TIA, n (%) | 0 (0) | 210 | 5 (1.8) | 284 | 8 (1.8) | 457 | 12 (3.0) | 405 | 10 (2.4) | 424 | 0.146 |
Stroke, n (%) | 2 (1.0) | 210 | 13 (4.6) | 284 | 22 (4.8) | 457 | 23 (5.7) | 405 | 32 (7.6) | 424 | 0.011 |
CAD, n (%) | 9 (4.3) | 210 | 24 (8.5) | 284 | 60 (13.1) | 457 | 101 (24.9) | 405 | 132 ((31.1) | 424 | <0.001 |
Previous MCI, n (%) | 5 (2.4) | 210 | 13 (4.6) | 284 | 32 (7.0) | 457 | 47 (11.6) | 405 | 66 (15.6) | 424 | <0.001 |
PAD, n (%) | 1 (0.5) | 210 | 6 (2.1) | 284 | 17 (3.7) | 457 | 25 (6.2) | 405 | 33 (7.8) | 424 | <0.001 |
Hyperlipidaemia, n (%) | 72 (34.3) | 210 | 103 (36.3) | 284 | 149 (32.6) | 457 | 121 (29.9) | 405 | 120 (28.3) | 424 | 0.169 |
Current smoker, n (%) | 11 (5.2) | 210 | 13 (4.6) | 284 | 21 (4.6) | 457 | 23 (5.7) | 405 | 25 (5.9) | 424 | 0.198 |
COPD, n (%) | 12 (5.7) | 210 | 11 (3.9) | 284 | 24 (5.3) | 457 | 43 (10.6) | 405 | 66 (15.6) | 424 | <0.001 |
Medication | |||||||||||
Beta-blockers, n (%) | 85 (40.5) | 210 | 115 (40.5) | 284 | 210 (46.0) | 457 | 184 (45.4) | 405 | 189 (44.6) | 424 | 0.466 |
Amiodaron, n (%) | 32 (15.2) | 210 | 46 (16.2) | 284 | 88 (19.3) | 457 | 88 (21.7) | 405 | 85 (20.1) | 424 | 0.227 |
VKA, n (%) | 58 (27.6) | 210 | 84 (29.6) | 284 | 155 (33.9) | 457 | 114 (28.2) | 405 | 106 (25.0) | 424 | 0.06 |
NOAC, n (%) | 32 (15.2) | 210 | 39 (13.7) | 284 | 69 (15.1) | 457 | 51 (12.6) | 405 | 47 (11.1) | 424 | 0.411 |
Diuretics, n (%) | 14 (6.7) | 210 | 41 (14.4) | 284 | 97 (21.2) | 457 | 107 (26.4) | 405 | 130 (30.7) | 424 | <0.001 |
‡After natural log transformation. Baseline characteristics by all five quintiles of hs-TnT.
CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease, DM, diabetes mellitus, hs-TnT, high-sensitive troponin T, MCI, myocardial infarction, NOAC, new oral anticoagulant, NT-proBNP, N-terminal pro-brain natriuretic peptide, PAD, peripheral artery disease, VKA, vitamin K antagonist.